ZEB1 Knockout HEK293 Cell Line
Cat.No.:
EDC07602
Species:
Human
Cell Name:
HEK293
Gene:
ZEB1
Gene ID:
6935
Size:
1×10⁶cells
ZEB1 Knockout Cell Line (HEK293) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDC07602 |
|---|---|
| Product Name | ZEB1 Knockout Cell Line (HEK293) |
| Cell Line | HEK293 |
| Cellosaurus ID | CVCL_0045 |
| Cell Line Synonyms | Hek293, HEK-293, HEK/293, (HEK)293, HEK 293, HEK,293, 293, 293 HEK, 293 Ad5, Graham 293, Graham-293, Human Embryonic Kidney 293 |
| Gene | ZEB1 |
| NCBI Gene ID | |
| Gene Synonyms | AREB6|BZP|DELTAEF1|FECD6|NIL2A|PPCD3|TCF8|ZFHEP|ZFHX1A |
| Summary |
This gene encodes a zinc finger transcription factor. The encoded protein likely plays a role in transcriptional repression of interleukin 2. Mutations in this gene have been associated with posterior polymorphous corneal dystrophy-3 and late-onset Fuchs endothelial corneal dystrophy. Alternatively spliced transcript variants encoding different isoforms have been described.[provided by RefSeq, Mar 2010]
|
| Associated Diseases | Non-tumor |
| Morphology | Adherent |
| Passage Ratio | 1/5,2days |
| Complete Culture Medium | DMEM + 10% FBS |
| Freezing Medium | 95% Complete culture medium+ 5% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: HEK293 | STR Info (Cell bank) Cell Line: HEK293 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | X | ||
| CSF1P0 | 12 | 11 | 12 | |
| D2S1338 | 19 | 19 | ||
| D3S1358 | 15 | 17 | 15 | 17 |
| D5S818 | 8 | 8 | 9 | |
| D7S820 | 11 | 12 | 11 | 12 |
| D8S1179 | 12 | 14 | 12 | 14 |
| D13S317 | 12 | 14 | 12 | 14 |
| D16S539 | 9 | 13 | 9 | 13 |
| D18S51 | 17 | 18 | 17 | 18 |
| D19S433 | 15 | 18 | 15 | 18 |
| D21S11 | 28 | 30.2 | 28 | 30.2 |
| FGA | 23 | 23 | ||
| Penta D | 9 | 10 | 9 | 10 |
| Penta E | 7 | 15 | 7 | 15 |
| TH01 | 7 | 9.3 | 7 | 9.3 |
| TPOX | 11 | 11 | ||
| vWA | 16 | 19 | 16 | 19 |
| D6S1043 | 11 | 11 | ||
| D12S391 | 19 | 21 | 11 | 15 |
| D2S441 | 11 | 15 | 11 | 15 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
FAQ
Which is better for studying ZEB1 function, ZEB1 Knockout HEK293 Cell Line or ZEB1 overexpression HEK293 Cell Line?
The choice depends on the experimental question, and for ZEB1 the answer is more context-dependent than for most factors. The Knockout line is appropriate when asking whether ZEB1 is required for repression of E-cadherin and other epithelial junction genes — although in HEK293, endogenous ZEB1 levels are modest, so the magnitude of phenotypic change may be smaller than in epithelial cancer lines. Overexpression is the more standard tool for driving EMT phenotypes in HEK293 and for activating mesenchymal gene programs.
For mechanistic dissection of ZEB1's regulatory logic — E-box binding, miR-200 circuit dynamics, co-repressor recruitment — the EDITGENE Knockout line in HEK293 provides a clean genetic background for reporter assays and rescue experiments. For phenotypic EMT studies, overexpression in HEK293 or work in endogenous-EMT cell lines (e.g., MDA-MB-231) is generally more appropriate.
What are the application scenarios for this model?
Primary applications:
• EMT marker profiling: E-cadherin and vimentin expression as direct readouts of ZEB1's epithelial gene repression function.
• miR-200/ZEB1 circuit analysis: reporter assays with miR-200 target sequences or ZEB1 promoter elements to dissect double-negative feedback loop dynamics.
• Transcription factor binding studies: ChIP or CUT&RUN to map ZEB1 occupancy at E-box-containing promoters.
• Rescue experiments: re-introduction of wild-type or domain-mutant ZEB1 constructs to assign specific functions to structural domains.
EDITGENE recommends this model for researchers investigating EMT transcriptional networks, ZEB1-regulated gene programs, and cancer invasion mechanisms.
Is this ZEB1 Knockout HEK293 Cell Line compatible with overexpression rescue experiments?
Yes, and rescue experiments are particularly important for ZEB1 because of its dose-sensitive role in EMT:
• Construct design: use a codon-modified ZEB1 sequence with a small C-terminal tag (FLAG, HA). Avoid large tags — ZEB1's multiple zinc fingers and homeodomain are sensitive to steric interference.
• Expression level control: this is critical for ZEB1. Overexpression beyond endogenous levels can drive EMT independently of any rescue effect, confounding interpretation. Inducible systems (Tet-On) with titration to physiological levels are strongly recommended.
• Domain mutant rescue: rescue with zinc finger DNA-binding mutants distinguishes ZEB1's transcriptional activity from protein-protein interaction functions. miR-200 binding site mutants in the 3' UTR can probe regulatory feedback.
• Functional readout: rescue should restore E-cadherin repression and mesenchymal gene expression. If endogenous miR-200 levels in HEK293 are high, they may suppress exogenous ZEB1 — consider miR-200-resistant rescue constructs (mutated 3' UTR seed sites).
HEK293's high transfection efficiency and stable lentiviral integration make it well-suited for ZEB1 rescue line generation.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
download